Sun Nov 23 09:48:48 SGT 2014  
    Botox® treatment, Singapore (SG)

Botox® treatment, Singapore (SG)


Botox® treatment, Singapore (SG) @singaporebotox_com: Botox® Cosmetic, Dysport®, BTX-A, botulinum toxin type A injection, wrinkle removal treatment clinic, Singapore. Cost/price for treating glabella frown lines, crow's feet, and horizontal forehead lines. Definitions, references, and latest news.


Botox® treatment is with the original Allergan Botox® Cosmetic
  • The units differ for different brands.
  • Price quoted is for average ladies face, with average musculature.
  • Muscular men might require up to twice as much.
  • Minimum charge is for 10 units.

Botox® price. Average Botox® cost.

AreaIU/spotSpotsTotal IUPrice @ SG$15/IU
Horizontal forehead lines2816SG$240
Glabellar frown lines4520SG$300
Crow's feet4624SG$360

Jaw slimming / face slimming / Botox® jaw reduction / Botox® jaw slimming / Botox® face slimming price.

AreaIU/spotSpotsTotal IUPrice @ SG$15/IU
Jaw reduction8 to 12656SG$840

Botox® is one of the trade names for botulinum toxin, which is a protein produced by the bacterium clostridium botulinum.

Aesthetic services available:

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Botox® treatment, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.


Latest News

Actavis Wins Bid To Buy Allergan
Fri, 21 Nov 2014 03:36:46 +0100 | Chemical and Engineering News
Pharmaceuticals: Botox maker avoids takeover by Valeant, sealing deal to preserve more of its R&D (Source: Chemical and Engineering News)

The Inhibitory Effect of Platelet-Rich Plasma on Botulinum Toxin Type-A: An Experimental Study in Rabbits
Fri, 21 Nov 2014 00:00:00 +0100 | Aesthetic Plastic Surgery

Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia
Wed, 19 Nov 2014 00:00:00 +0100 | Parkinsonism and Related Disorders
The development of secondary non-response (SNR) to botulinum neurotoxin type-A (BoNT-A) is considered a key issue in the management of cervical dystonia (CD). This case-controlled study was performed to systematically identify factors influencing SNR during BoNT-A therapy. (Source: Parkinsonism and Related Disorders)

The cost‐effectiveness of sacral nerve stimulation for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK
Wed, 19 Nov 2014 00:00:00 +0100 | BJU International
ConclusionIn the management of patients with idiopathic OAB wet, the results of this cost‐utility analysis favors SNS (PNE or TLE) over PTNS or OMT, and the most efficient treatment strategy is SNS PNE over BoNT‐A over a 10 year period. (Source: BJU International)

Understanding and treating vaginismus: a multimodal approach
Tue, 18 Nov 2014 13:13:21 +0100 | International Urogynecology Journal

Snapshot: Botox maker’s $66B deal + Ford debuts 500-horsepower Mustang
Tue, 18 Nov 2014 13:12:00 +0100 | Health Care:Pharmaceuticals headlines

Actavis to Buy Allergan for $66 Billion
Tue, 18 Nov 2014 02:18:49 +0100 | Health
Actavis agreed to pay $66 billion in cash and stock for Allergan in a deal that appears to have thwarted a hostile takeover of the Botox maker by Valeant and Bill Ackman. (Source: Health)

Actavis signs agreement to buy Botox-maker Allergan for $66bn
Tue, 18 Nov 2014 00:00:00 +0100 | Pharmaceutical Technology
Ireland-based pharmaceutical company Actavis has signed an agreement to acquire US-based Botox-maker Allergan for $66bn or $219 per share. (Source: Pharmaceutical Technology)

Allergan Sides With More Aggressive Dealmaker By Picking Actavis Over Valeant
Mon, 17 Nov 2014 22:16:00 +0100 | Healthcare News
Botox-maker Allergan is cutting a sweeter deal with an even more acquisitive and hard-charging generic drug maker in Actavis (Source: Healthcare News)

Actavis Nears Deal to Acquire Allergan
Mon, 17 Nov 2014 15:42:01 +0100 | Health
Actavis is nearing a deal to acquire Allergan in a tie-up that would likely be the year’s largest and could help shield the Botox maker from hostile suitor Valeant. (Source: Health)